Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent
A phase 1/2 trial of Cemiplimab, Tocilizumab in ovarian cancer and endometrial cancer, run by Regeneron Pharmaceuticals, now recruiting.
Overview
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers is a phase 1/2 interventional study registered as NCT03564340 by Regeneron Pharmaceuticals, with 890 participants planned, started 2018-05-21 and due to reach its primary completion in 2027-05-10. Interventions recorded: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab. Conditions listed: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata
Shares Ubamatamab, Cemiplimab, Regeneron, Endometrial cancer.
- TrialInvestigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Shares Ubamatamab, Cemiplimab, Regeneron, Ovarian cancer.
- TrialA Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shares Ubamatamab, Regeneron.
- TrialStudy of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Shares Cemiplimab, Regeneron.
- TrialA Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small
Shares Cemiplimab, Regeneron.
- TrialA Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta
Shares Cemiplimab, Regeneron.
- TrialREGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate
Shares Cemiplimab, Regeneron.
- TrialA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Hav
Shares Cemiplimab, Regeneron.